Search
Now showing items 1-4 of 4
Entry and competition in generic biologics
(Managerial and Decision Economics, 2007-06-01)
Patents for several blockbuster biological products are expected to expire soon. The
Food and Drug Administration is examining whether biologies can and should be treated
like pharmaceuticals with regard to generics. In ...
Encouraging innovative treatment of neglected diseases through priority review vouchers
(Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval
safety surveillance. There have been no systematic assessments of spending on postapproval
safety. We surveyed drug manufacturers regarding ...
Developing drugs for developing countries.
(Health Aff (Millwood), 2006-03)
Infectious and parasitic diseases create enormous health burdens, but because most
of the people suffering from these diseases are poor, little is invested in developing
treatments. We propose that developers of treatments ...